Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-06-30

FDA Approved: RAMIPRIL — Supplemental Application (Zydus Lifesciences Limited)

View source ↗

Summary

FDA approved a supplemental application for ramipril submitted by Zydus Lifesciences Limited under ANDA078832.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ramipril (ramipril)

Snippet

SUPPL AP for RAMIPRIL (RAMIPRIL)